ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0072

Immunosuppression Use in Primary Antiphospholipid Antibody Positive Patients: Descriptive Analysis of the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Abstract Number: 0073

Anti-Domain 1 Antibody Fluctuation over Time in Patients with Persistently Positive Antiphospholipid Antibodies: Results from the Aps Action Clinical Database and Repository (“Registry”)
Abstract Number: 0074

Association of Anti-phospholipid Antibodies (aPL) with Poor Clinical Outcomes in Hospitalized Patients with COVID-19
Abstract Number: 0075

Endothelial Cell-activating Antibodies in COVID-19
Abstract Number: 0076

Predicting the Transitions Between Lupus Anticoagulant Status and Thrombosis in SLE Using a Multi-state Markov Model
Abstract Number: 0077

Association of Lupus Nephritis and Other Clinical Features with Antiphospholipid Antibody Positivity Among Patients with Systemic Lupus Erythematosus
Abstract Number: 0078

Frequency and Clinical Characteristics of Secondary Antiphospholipid Syndrome in Systemic Lupus Erythematosus: The Georgia Lupus Registry
Abstract Number: 0079

Association Between Preconception Complement Levels and Use of Hydroxychloroquine with Pregnancy Outcome in Patients with Primary Antiphospholipid Syndrome and Carriers of Antiphospholipid Antibodies: An International Multicenter Study
Abstract Number: 0080

One Point Increase in the Initial Damage as Measured by the Damage Index for Antiphospholipid Syndrome Predicts Mortality in a Multi-Ethnic Group of Thrombotic Antiphospholipid Syndrome Patients
Abstract Number: 0081

Thrombin Generation Assay and Lupus Anticoagulant Identify Different Populations of Patients with Antiphospholipid Antibodies
Abstract Number: 0082

Association of Current Cigarette Smoking and Obesity with Antiphospholipid Antibodies and Thrombosis in 1216 International Patients Evaluated for Suspected Antiphospholipid Syndrome (APS)
Abstract Number: 0083

Cardiac Valve Surgery Outcomes in the Antiphospholipid Syndrome
Abstract Number: 0084

COVID-19 Pneumonia in Two Hospitals: Similar Outcomes Despite Differential Use of Tocilizumab
Abstract Number: 0085

Association of CD20 Inhibitor Use with Severe COVID-19 Outcomes
Abstract Number: 0086

SARS-CoV-2 Infection and COVID-19 Outcomes in Rheumatic Disease: A Systematic Literature Review

« Previous Page
1
…
6
7
8
9
10
…
132
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].